NCT01652599View on ClinicalTrials.gov

Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

November 30, 2013

Conditions
Immune Thrombocytopenic Purpura
Interventions
DRUG

Eltrombopag and dexamethasone

Eltrombopag 50 mg PO days 5-32 Dexamethasone 40 mg PO days 1-4

Trial Locations (1)

64460

"Hospital Universitario Dr. Jose E. Gonzalez UANL", Monterrey

All Listed Sponsors
lead

Hospital Universitario Dr. Jose E. Gonzalez

OTHER

NCT01652599 - Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT | Biotech Hunter | Biotech Hunter